(Q62054749)
Statements
IFM2014-01 (English)
0 references
Multicenter Open Label Phase 2 Single Arm Study of Ixazomib, Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Characterized With Genomic Abnormalities of Adverse Adverse Prognostic (English)
0 references
1 October 2018
0 references
1 October 2023
0 references
70
0 references
18 year
0 references